Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd is a London-based biotechnology company incorporated in 1998 and listed on NASDAQ under the ticker TLSA as common stock. The company focuses on developing therapies for neurodegenerative and lung diseases, with a research pipeline centered on immunology and inflammatory conditions. Its lead candidate, Foralumab (TZLS-401), is a human anti-CD3 monoclonal antibody being studied across a range of indications, including Crohn’s disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Tiziana is also advancing TZLS-501, a fully human monoclonal antibody that targets the IL-6 receptor for potential use in inflammatory and oncology indications.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TLSA
|
$0.59
|
-34.2% Downside
|
Overvalued
|
$7.96
|
794.3% Upside
|
Bargain
|
Weak
|
0.0%
|
September 24, 2026
|
2,249.7x
|
115.1 M
|
111 M
|
0.4%
|
51.4%
|
-56.9
|
69.8%
|
